Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Receivables: 2013-2024

Historic Receivables for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $32.4 million.

  • Ocular Therapeutix's Receivables rose 1.76% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.8 million, marking a year-over-year increase of 4.94%. This contributed to the annual value of $32.4 million for FY2024, which is 23.72% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Receivables of $32.4 million as of FY2024, which was up 23.72% from $26.2 million recorded in FY2023.
  • Ocular Therapeutix's Receivables' 5-year high stood at $32.4 million during FY2024, with a 5-year trough of $12.3 million in FY2020.
  • For the 3-year period, Ocular Therapeutix's Receivables averaged around $26.6 million, with its median value being $26.2 million (2023).
  • Data for Ocular Therapeutix's Receivables shows a peak YoY surged of 380.85% (in 2020) over the last 5 years.
  • Over the past 5 years, Ocular Therapeutix's Receivables (Yearly) stood at $12.3 million in 2020, then spiked by 72.50% to $21.1 million in 2021, then climbed by 0.90% to $21.3 million in 2022, then grew by 22.76% to $26.2 million in 2023, then increased by 23.72% to $32.4 million in 2024.